TRPML1 agonist / Merck (MSD) - LARVOL DELTA

Caraway Therapeutics to Participate at Two Upcoming Investor Events (Businesswire) - "Caraway Therapeutics today announced that the Company will be presenting at the Stifel CNS Days event on Tuesday, March 29, 2022, at 3:00pm Eastern Time. Caraway’s Chief Executive Officer, Martin D. Williams, will highlight recent advances in the company’s lead program targeting the lysosomal cation channel, TRPML1, for the treatment of GBA-Parkinson’s disease (GBA-PD) and other rare genetic diseases."

Preclinical • CNS Disorders • Parkinson's Disease